Therapeutical Class：Polymyxin antibiotics

Indication：Treatment of infections due to sensitive strains of certain G(-) bacilli which are resistant to other antibacterials or in patients allergic to other antibacterials.

Administraton：

Susceptible infections: IM or IV: 2.5-5 mg colistin/kg/day in 2~4 divided doses, depending on severity of infection.

IH (unlabeled use): in 3-4 ml N/S via nebulizer. <40 kg: 40 mg CMS (1/4 vial) q12h. >40 kg: 80 mg CMS (1/2 vial) q12h.

Recurrent lung infection: 160 mg CMS (1 vial) q8h.

Renal impairment: Scr 1.3-1.5 mg/dL, 150-230 mg colistin/day in 2 divided doses; Scr 1.6-2.5 mg/dL, 133-150 mg colisitn/day in 1-2 divided dose; Scr 2.6-4.0 mg/dL, 100-150 mg colistin/day every 36 hrs.

Adverse Effect：Generalized pruritus, rash, urticaria, gastrointestinal disturbance,pseudomembranous enterocolitis, leukopenia,neuromuscular blockade finding,dizziness,vertigo, neurotoxicity, nephrotoxicity, acute respiratory failure(IH route), respiratory tract paralysis, drug fever.

Pregnancy Risk：C

Supply：Colimycin XE “Colimycin” Inj 2000000U(克痢黴素 東洋) ＜10865＞